— Know what they know.
Not Investment Advice

PSTX NASDAQ

Poseida Therapeutics, Inc.
1W: -1.0% 1M: +1.5% 3M: +269.6% 1Y: +194.1% 3Y: +38.5%
$9.50
Last traded 2025-01-08 — delisted
NASDAQ · Healthcare · Biotechnology · $925.9M mcap · 65M float · 2.78% daily turnover

Balance Sheet Trends

Total Assets
$274M -22.2% ▼
5Y CAGR: +43.4%
Total Liabilities
$170M +3.6% ▲
5Y CAGR: +6.9%
Shareholders Equity
$104M -44.7% ▼
Cash & Investments
$212M -24.9% ▼
5Y CAGR: +47.5%
Total Debt
$85M -3.8% ▼
5Y CAGR: +34.9%
Net Debt
$41M +455.3% ▲

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2019FY2020FY2021FY2022FY2023
— Assets —
Cash$88M$84M$206M$81M$44M
Short-Term Investments$38M$225M$0$201M$168M
Cash & ST Investments$125M$309M$206M$282M$212M
Net Receivables$0$0$0$9M$9M
Inventory$0$0$0$0$0
Other Current Assets$1M$2M$5M$5M$4M
Total Current Assets$127M$314M$214M$299M$226M
Property, Plant & Equip.$11M$48M$48M$47M$41M
Goodwill & Intangibles$6M$6M$6M$6M$6M
Long-Term Investments-$2M-$9M-$9M-$9M$0
Other Non-Current Assets$3M$4M$2M$1M$1M
Total Non-Current Assets$20M$57M$55M$53M$47M
Total Assets$147M$371M$269M$352M$274M
— Liabilities —
Accounts Payable$5M$763K$9M$2M$3M
Short-Term Debt$3M$5M$6M$0$0
Deferred Revenue$12M$23M$4M$20M$31M
Other Current Liabilities$11M-$3M$8M$15M$18M
Total Current Liabilities$22M$30M$43M$54M$71M
Long-Term Debt$26M$29M$55M$58M$59M
Other Non-Current Liab.$5M$25M-$20M$6M$3M
Total Non-Current Liabilities$275M$79M$70M$110M$99M
Total Liabilities$297M$110M$113M$164M$170M
— Equity —
Common Stock$2K$6K$6K$9K$10K
Retained Earnings-$152M-$282M-$407M-$471M-$594M
Accumulated OCI$19K$5K$0-$149K$126K
Total Stockholders Equity-$150M$262M$156M$188M$104M
Total Liabilities & Equity$147M$371M$269M$352M$274M
— Key Metrics —
Total Debt$29M$59M$61M$89M$85M
Net Debt-$59M-$25M-$145M$7M$41M
Total Investments$36M$216M-$9M$192M$168M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms